Passive immunization against pyroglutamate-3 amyloid-β Reduces plaque burden in Alzheimer-like transgenic mice: A pilot study

Neurodegenerative Diseases

Volumn 10, Issue 1-4, 2012, Pages 265-270

  Frost, Jeffrey L ^a   Liu, Bin ^a   Kleinschmidt, Martin ^b   Schilling, Stephan ^b   Demuth, Hans Ulrich ^b   Lemere, Cynthia A ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PROBIODRUG AG   (Germany)

^c NRB 636F ^*  (United States)

Author keywords

Alzheimer's disease; Immunotherapy; Monoclonal antibody; Pyroglutamate 3 amyloid ; Transgenic mice

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; MAB07 1; MONOCLONAL ANTIBODY; PYROGLUTAMATE 3 AMYLOID BETA PROTEIN; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HEMORRHAGE; CEREBELLUM; CONTROLLED STUDY; GLIOSIS; HIPPOCAMPUS; IMMUNOTHERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PILOT STUDY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; ANTIBODIES; BRAIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIOSIS; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PILOT PROJECTS; PLAQUE, AMYLOID; PRESENILIN-1; PYRROLIDONECARBOXYLIC ACID; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84862816040     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000335913     Document Type: Article

References (20)

1. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
2. Saido TC, Iwatsubo T, Mann DMA, Shimada H, Ihara Y, Kawashima S: Dominant and differential deposition of distinct3β 42-amyloid peptide species, A3β N3(p3) , in senile plaques. Neuron 1995; 14: 457-466.
3. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ: Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996; 3: 16-32.
4. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango- L JC, Anthony DC, Koo E, Goate A, Selkoe DJ, Arango-V JC: The E280A presenilin 1 Alzheimer mutation produces increased A3β 42 42 deposition and severe cerebellar pathology. Nat Med 1996; 2: 1146-1150.
5. Miravalle L, Calero M, Takao M, Roher A, Ghetti B, Vidal R: Amino-terminally truncated A3β peptide species are the main component of cotton wool plaques. Biochemistry 2005; 44: 10810-10821.
6. Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen P, Malthaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannsfelt L, Bayer TA: Pyroglutamate Abeta pathology in APP/PS1KO mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 2010; 117: 85-96.
7. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth H: Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett 2004; 563: 191-196.
8. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S: Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 1996; 215: 173-176.
9. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, Demuth H-U: On the seeding and oligomerization of the pGluamyloid peptides (in vitro). Biochemistry 2006; 45: 12393-12399.
10. He W, Barrow C: The A3β 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaques have greaterβ -sheet forming and aggregation propensities in vitro than full length A3β . Biochemistry 1999; 38: 10871-10877.
11. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth H-U, Bayer T: Intraneuronal pyroglutamate- Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 2009; 118: 487-496.
12. Guntert A, Dobeli H, Bohrmann B: High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 2006; 143: 461-475.
13. Piccini A, Zanusso G, Borghi R, Noviello C, Monaco S, Russo R, Damonte G, Armirotti A, Gelati M, Giordano R, Zambenedetti P, Russo C, Ghetti B, Tabaton M: Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype. Arch Neurol 2007; 64: 738-745.
14. Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armirotti A, D'Arrigo C, Bachi A, Cattaneo A, Canale C, Torrassa S, Saido T, Markesbery W, Gambetti P, Tabaton M:3β 42-amyloid is different in normal aging and in Alzheimer's disease. J Biol Chem 2005; 280: 34186-34192.
15. Cynis J, Scheel E, Saido TC, Schilling S, Demuth HU: Amyloidogenic processing of the amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry 2008; 47: 7405-7413.
16. Jankowsky J, Fadale D, Anderson J, Xu G, Gonzales V, Jenkins N, Copeland N, Lee M, Younkin L, Wagner S, Younkin S, Borchelt D: Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004; 13: 159-170.
17. Garcia-Alloza M, Robbins E, Zhang-Nunes S, Purcell S, Betensky R, Raju S, Prada C, Greenberg S, Bacskai B, Frosch M: Characterization of amyloid deposition in the APPswe/ PS1dE9 mouse model of Alzheimer's disease. Neurobiol Dis 2006; 24: 516-524.
18. Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD: Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 2002; 23: 991-1000.
19. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Franke M, Kehlen A, Holzer M, Hutter- Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montage D, Demuth H-U, Rossner S: Glutaminyl cyclase inhibition attenuates pyroglutamate A3β and Alzheimer's diseaselike pathology. Nat Med 2008; 14: 1106-1111.
20. Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L, Bayer TA: Identification of low molecular weight pyroglutamate A3β 42 oligomers in Alzheimer disease. J Biol Chem 2010; 285: 41517-41524.